Efficacy of Tixagevimab-Cilgavimab Against Omicron in Hematologic Malignancies

Overview

This retrospective study evaluated 13 patients with hematologic malignancies infected with Omicron SARS-CoV-2 treated with tixagevimab-cilgavimab. Asymptomatic patients treated early avoided severe COVID-19, while outcomes in symptomatic patients requiring oxygen were variable, with some recovering and others experiencing fatal progression.

Background

Patients with hematologic malignancies are at high risk for severe COVID-19 and have higher mortality rates compared to immunocompetent individuals. The Omicron variant exhibits immune escape from vaccine-induced antibodies, reducing efficacy of some monoclonal antibodies. Tixagevimab-cilgavimab retains partial neutralizing activity against Omicron and is authorized for treatment in high-risk patients with low anti-S IgG levels. Data on its efficacy specifically in hematologic malignancy patients infected with Omicron are limited.

Data Highlights

Key Findings

• All five asymptomatic patients treated early with tixagevimab-cilgavimab recovered without additional COVID-19 treatment and resumed chemotherapy.
• Among eight symptomatic patients requiring oxygen, three fully recovered with tixagevimab-cilgavimab ± steroids, one improved after convalescent plasma, and four died due to COVID-19 progression.
• Median anti-S IgG levels increased substantially after tixagevimab-cilgavimab administration, indicating effective antibody presence from treatment rather than natural immune response.
• Some symptomatic patients experienced delayed worsening of COVID-19 pneumonia despite initial improvement, highlighting the risk of prolonged disease course in this population.
• Tixagevimab-cilgavimab at 300–300 mg may prevent progression to severe disease if administered early in high-risk hematologic malignancy patients with low anti-S IgG.

Clinical Implications

Early administration of tixagevimab-cilgavimab in asymptomatic hematologic malignancy patients with low anti-S IgG may prevent severe COVID-19 and allow continuation of chemotherapy. However, in symptomatic patients requiring oxygen, outcomes remain variable, and additional therapies may be needed. Monitoring for delayed respiratory deterioration is important in this vulnerable population.

Conclusion

Tixagevimab-cilgavimab shows promise in preventing severe COVID-19 progression when given early to high-risk hematologic malignancy patients infected with Omicron. Further studies are needed to optimize treatment strategies for symptomatic patients with advanced disease.

References

1. 1 -- High mortality of COVID-19 in hematologic malignancies
2. 2 -- Omicron variant immune escape and monoclonal antibody efficacy
3. 3 -- Omicron associated with decreased hospital admission and mortality
4. 4 -- Mortality rate among hospitalized hematologic malignancy patients
5. 5 -- Randomized trial of tixagevimab-cilgavimab showing mortality benefit
6. 6 -- Prophylactic efficacy of tixagevimab-cilgavimab against Omicron
7. 7 -- Additional data supporting prophylactic use of tixagevimab-cilgavimab